Rawia Mohamed: Biomarkers in Gastroesophageal Cancer
Rawia Mohamed, Head of the Anatomical Pathology Department at Burjeel Medical City and an Associate Professor at Khalifa University, shared on LinkedIn:
“This slide is part of a presentation at the GI Oncology Summit, where I presented Biomarkers in Gastric cancer. This slide discusses HER2-low in Gastroesophageal Cancer (GC/GEJC) from a real-world Italian perspective based on 1,189 cases.
Here some of the Key Points:
1. HER2 Status in GC/GEJC Patients:
The left pie chart shows that 88.1% of cases were not candidates for trastuzumab therapy (HER2-negative).
Only 11.9% were HER2-positive, meaning they were good candidates for trastuzumab therapy.
2. Potential Benefit from T-DXd (Trastuzumab Deruxtecan) Therapy:
The right pie chart further categorizes HER2-negative cases, showing that 28.3% were HER2-low.
HER2-low patients may benefit from T-DXd therapy, as suggested by the DESTINY-GASTRIC01 trial.
3. Clinical Implications:
32.2% of HER2-negative tumors were found to be HER2-low, indicating a new therapeutic window for T-DXd.
HER2-low status is more prevalent in biopsy specimens (p > 0.0001).
There is high inter-center variability in HER2-low classification (p = 0.0005), meaning consistency in HER2 assessment remains a challenge.
Relevance:
This study highlights the importance of identifying HER2-low cases in GC/GEJC, as these patients might benefit from targeted therapies like T-DXd, expanding treatment options beyond standard HER2-positive cases.
The findings suggest the need for standardized HER2 assessment to optimize patient selection for T-DXd therapy.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023